Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance.

He B, Gampe RT Jr, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT, Wilson EM.

Mol Cell. 2004 Nov 5;16(3):425-38.

2.

Principles for modulation of the nuclear receptor superfamily.

Gronemeyer H, Gustafsson JA, Laudet V.

Nat Rev Drug Discov. 2004 Nov;3(11):950-64. Review.

PMID:
15520817
3.

Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.

Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J.

Cancer Cell. 2004 Jun;5(6):597-605.

4.

The androgen receptor gene mutations database (ARDB): 2004 update.

Gottlieb B, Beitel LK, Wu JH, Trifiro M.

Hum Mutat. 2004 Jun;23(6):527-33. Erratum in: Hum Mutat. 2004 Jul;24(1):102.

PMID:
15146455
5.

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Taplin ME, Balk SP.

J Cell Biochem. 2004 Feb 15;91(3):483-90. Review.

PMID:
14755679
6.

A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor.

Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson LM, Marsh JL, Diamond MI.

Neuron. 2003 Nov 13;40(4):685-94.

7.

Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.

Nightingale J, Chaudhary KS, Abel PD, Stubbs AP, Romanska HM, Mitchell SE, Stamp GW, Lalani el-N.

Neoplasia. 2003 Jul-Aug;5(4):347-61. doi: 10.1016/S1476-5586(03)80028-3.

8.

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663.

J Clin Oncol. 2003 Jul 15;21(14):2673-8.

PMID:
12860943
9.

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators.

JAMA. 2003 Jun 25;289(24):3243-53.

PMID:
12824205
10.

Conformation of CCAAT/enhancer-binding protein alpha dimers varies with intranuclear location in living cells.

Schaufele F, Wang X, Liu X, Day RN.

J Biol Chem. 2003 Mar 21;278(12):10578-87. Epub 2003 Jan 16.

11.
12.

Creating new fluorescent probes for cell biology.

Zhang J, Campbell RE, Ting AY, Tsien RY.

Nat Rev Mol Cell Biol. 2002 Dec;3(12):906-18. Review.

PMID:
12461557
13.

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group.

Lancet. 2002 Jun 22;359(9324):2131-9. Erratum in: Lancet 2002 Nov 9;360(9344):1520.

PMID:
12090977
14.

Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction.

He B, Lee LW, Minges JT, Wilson EM.

J Biol Chem. 2002 Jul 12;277(28):25631-9. Epub 2002 May 8.

15.

Combinatorial control of gene expression by nuclear receptors and coregulators.

McKenna NJ, O'Malley BW.

Cell. 2002 Feb 22;108(4):465-74. Review.

16.

Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.

Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P.

J Med Chem. 2002 Mar 28;45(7):1439-46.

PMID:
11906285
17.

Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.

Weatherman RV, Chang CY, Clegg NJ, Carroll DC, Day RN, Baxter JD, McDonnell DP, Scanlan TS, Schaufele F.

Mol Endocrinol. 2002 Mar;16(3):487-96.

PMID:
11875107
18.

Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.

Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR Jr, Weinmann R, Einspahr HM.

Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4904-9.

19.

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM.

Cancer Res. 2001 Apr 1;61(7):2892-8.

20.

Supplemental Content

Support Center